With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...